Fact-checking

Inherited cancer and genetic testing - looking beyond the myths

Cancer is a genetic disease caused by abnormal changes over time to genes that control cell function, typically starting in a single cell (an acquired mutation) and often not linked to an inherited genetic mutation. In other words, most cancers happen by chance.

Only about 5 to 10 percent of cancers are due to an inherited genetic mutation, says Monique Lubaton, MGC, CGC, cancer genetic counselor at the Alvin & Lois Lapidus Cancer Institute at LifeBridge Health. Nonetheless, if you have a strong family history of cancer, genetic testing may be indicated for you. Patterns to look out for in a family are breast, ovarian, prostate or pancreatic cancers (especially if you are of Ashkenazi Jewish descent), as well as colon and uterine cancers. 

Lubaton helps debunk myths about inherited cancers and genetic testing:

Myth: I tested negative for a mutation in BRCA1 and BRCA2, so I do not have a hereditary cancer syndrome.

Photo

It is estimated that one in 500 individuals in the general population has a BRCA1 or BRCA2 mutation, while approximately one in 40 in the Ashkenazi Jewish population (Central or Eastern European) carries a mutation in one of these two genes. 

While BRCA1/2 mutations are the most common cause of with hereditary breast or ovarian cancer, testing negative for those two does not mean there is no underlying hereditary cancer syndrome, Lubaton says. “There are a number of other genes that are associated with hereditary cancer syndromes,” she says.

Myth: If I have an inherited genetic mutation, I will get cancer in my lifetime.

It is not a given that people with a hereditary cancer syndrome will actually develop cancer. Lubaton says that most hereditary cancer syndromes have “moderate to high” risk levels, but that “with guided management, those risks can be reduced.”

Myth: A woman cannot get a genetic mutation from her father.

Almost all hereditary cancer syndrome mutations can be passed down by either gender, Lubaton says. Both men and women can be carriers of a BRCA1 or BRCA2 mutation, but inherited alterations in these genes make female carriers more susceptible to developing breast and ovarian cancers.

Myth: I’ve already had cancer, so it doesn’t matter whether or not I know if I have an inherited genetic mutation.

There are now targeted therapies for individuals with genetic mutations

Monique Lubaton

Individuals who are carriers of a hereditary cancer syndrome can be at increased risks for multiple primary cancers over their lifetime, hence why it’s important to pursue genetic testing and learn about mutation status. “Also something important to know, there are now targeted therapies for individuals with genetic mutations,” Lubaton says.

Myth: Genetic testing is expensive and not covered by medical insurance.

Lubaton insists that genetic testing has become much more affordable in recent years. “I think a lot of people, when they think about [genetic testing], they think it is very, very expensive, and it did used to be very, very expensive. But fortunately, over time, and with better medical coverage and competition, the cost of genetic testing has been significantly reduced,” Lubaton says, adding that testing is “well-covered” by insurance.

Other signs of hereditary cancer syndrome include:

  • Cancer found at an early age (under 50)
  • Three or more family members (on the same side of the family) with the same type of cancer
  • One or more family members with multiple cancers
  • Rare cancers like medullary thyroid cancer, paragangliomas and male breast cancer
  • History of more than 10 colon polyps


Source: LifeBridge Health

07.04.2018

Read all latest stories

Related articles

Photo

Genetic mutations

'Invade and evade': Deciphering pancreatic cancer’s tactics

Two known gene mutations induce pathways that enhance pancreatic cancer’s ability to invade tissues and evade the immune system. Researchers report the molecular details of this process providing…

Photo

Against rebound

Pancreatic cancer: Genome-wide analysis reveals new strategies

For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of…

Photo

Large study

Five novel genetic changes linked to pancreatic cancer risk

In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and…

Related products

Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Eppendorf – BioSpectrometer fluroescence

Research Use Only (RUO)

Eppendorf – BioSpectrometer fluroescence

Eppendorf AG
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Eppendorf – μCuvette G1.0

Research Use Only (RUO)

Eppendorf – μCuvette G1.0

Eppendorf AG
Orion Diagnostica Oy – Orion GenRead

Amplification

Orion Diagnostica Oy – Orion GenRead

Orion Diagnostics Oy